{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:55:07Z","timestamp":1792086907983,"version":"4.4.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.blre.2025.101271","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:23:24Z","timestamp":1738257804000},"page":"101271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies"],"prefix":"10.1016","volume":"71","author":[{"given":"Mohamed Nazem","family":"Alibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101271_bb0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.5603\/AHP.2021.0092","article-title":"Prevalence and demographic characteristics of Hodgkin lymphoma in Colombia, according to the Ministry of Health data","volume":"52","author":"Ar\u00e9valo-Zambrano","year":"2021","journal-title":"Acta Haematol Pol"},{"key":"10.1016\/j.blre.2025.101271_bb0010","first-page":"6","article-title":"Hodgkin lymphoma (primer)","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.blre.2025.101271_bb0015","series-title":"StatPearls, Treasure Island (FL)","author":"Jamil","year":"2025"},{"key":"10.1016\/j.blre.2025.101271_bb0020","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2025.101271_bb0025","first-page":"176","article-title":"Challenges in the diagnosis of Hodgkin lymphoma in a child with asthma","volume":"8","author":"Belykh","year":"2024","journal-title":"\u0420\u041c\u0416 \u041c\u0415\u0414\u0418\u0426\u0418\u041d\u0421\u041a\u041e\u0415 \u041e\u0411\u041e\u0417\u0420\u0415\u041d\u0418\u0415"},{"key":"10.1016\/j.blre.2025.101271_bb0030","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.1280","article-title":"The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study","volume":"7","author":"Ebied","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2025.101271_bb0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13000-022-01272-x","article-title":"Aberrant synaptophysin expression in classic Hodgkin lymphoma","volume":"17","author":"Im","year":"2022","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.blre.2025.101271_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/his.14836","article-title":"The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics","volume":"82","author":"Kilsdonk","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.blre.2025.101271_bb0045","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-18-1133","article-title":"Targeting Cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin Lymphoma using the dual PI3Kdelta\/gamma inhibitor RP6530","volume":"25","author":"Locatelli","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2025.101271_bb0050","first-page":"64","volume":"2","author":"Schiavoni","year":"2018","journal-title":"Genet Class Hodgkin lymphoma HemaSphere"},{"key":"10.1016\/j.blre.2025.101271_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/cancers14010009","article-title":"Immune-proteome profiling in classical Hodgkin Lymphoma tumor diagnostic tissue","volume":"14","author":"Gholiha","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101271_bb0060","first-page":"2187","article-title":"Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma","volume":"141","author":"Carbone","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0065","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"Kuppers","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2025.101271_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/annonc\/13.S1.11","article-title":"Biology of Hodgkin\u2019s lymphoma","volume":"13","author":"K\u00fcppers","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2025.101271_bb0075","first-page":"233","article-title":"Cellular origin and clonality of classic Hodgkin\u2019s lymphoma: immunophenotypic and molecular studies","author":"Stein","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2025.101271_bb0080","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg cells in Hodgkin\u2019s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2025.101271_bb0085","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0090","first-page":"21","article-title":"\u00dcber eine eigenartige unter dem Bilde der Pseudoleukamie verlaufende Tuberculose des lymphatischen Apparates","volume":"19","author":"Sternberg","year":"1898","journal-title":"Ztschr Heilk"},{"key":"10.1016\/j.blre.2025.101271_bb0095","first-page":"133","article-title":"On the pathological changes in Hodgkin\u2019s disease, with especial reference to its relation to tuberculosis","volume":"10","author":"Reed","year":"1902","journal-title":"Johns Hopkins Hosp Rep"},{"key":"10.1016\/j.blre.2025.101271_bb0100","doi-asserted-by":"crossref","first-page":"20729","DOI":"10.1073\/pnas.1312509110","article-title":"Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells","volume":"110","author":"Rengstl","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2025.101271_bb0105","series-title":"Classic Hodgkin Lymphoma","author":"Wright","year":"2024"},{"key":"10.1016\/j.blre.2025.101271_bb0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biocel.2003.10.025","article-title":"The Hodgkin and Reed\/Sternberg cell","volume":"37","author":"Kuppers","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.blre.2025.101271_bb0115","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood-2014-04-571745","article-title":"Nodular sclerosis Hodgkin lymphoma with classic Reed-Sternberg cells","volume":"124","author":"Li","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0120","series-title":"Reed Sternberg Cells","author":"Aggarwal","year":"2019"},{"key":"10.1016\/j.blre.2025.101271_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000971","article-title":"CAR-T cell therapy for classical Hodgkin Lymphoma","volume":"7","author":"Katsin","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2025.101271_bb0130","first-page":"183","article-title":"Brentuximab vendotin and diffuse large B-cell lymphoma","volume":"3","author":"Gandhi","year":"2015","journal-title":"J Hematol Thromb Dis"},{"key":"10.1016\/j.blre.2025.101271_bb0135","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/PAS.0000000000000242","article-title":"A single slide multiplex assay for the evaluation of classical Hodgkin lymphoma","volume":"38","author":"Hollman-Hewgley","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2025.101271_bb0140","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.3390\/cancers16234070","article-title":"Pathobiological features and therapeutic opportunities linked to TNF family member expression in classic Hodgkin Lymphoma","volume":"16","author":"Alibrahim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101271_bb0145","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.31557\/APJCP.2018.19.12.3463","article-title":"Expression of PAX-5 in B cell Hodgkin and non Hodgkin Lymphoma","volume":"19","author":"Khan","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.blre.2025.101271_bb0150","first-page":"701","article-title":"Expression of B-cell antigens by Hodgkin\u2019s and Reed-Sternberg cells","volume":"139","author":"Schmid","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2025.101271_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1155\/2007\/362360","article-title":"A definitive diagnosis of primary Hodgkin lymphoma on endoscopic biopsy material utilizing in-depth immunohistochemical analysis","volume":"21","author":"Horne","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.blre.2025.101271_bb0160","first-page":"66","article-title":"Aggressive behaviour of Hodgkin\u2019s-like lymphoma in a domestic ferret","author":"Kim","year":"2021","journal-title":"Vet Med"},{"key":"10.1016\/j.blre.2025.101271_bb0165","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/modpathol.2009.54","article-title":"Lymphocyte-rich classical Hodgkin\u2019s lymphoma: distinctive tumor and microenvironment markers","volume":"22","author":"Nam-Cha","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2025.101271_bb0170","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/jcp.2009.075127","article-title":"Is fascin really a useful marker in distinguishing between classical Hodgkin\u2019s lymphoma and various types of non-Hodgkin\u2019s lymphomas in difficult cases?","volume":"63","author":"Idrees","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2025.101271_bb0175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12253-010-9335-x","article-title":"Aberrant cytoplasmic expression of cyclin B1 protein and its correlation with EBV-LMP1, P53 and P16(INK4A) in classical Hodgkin lymphoma in China","volume":"17","author":"Zhao","year":"2011","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.blre.2025.101271_bb0180","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood-2002-08-2577","article-title":"Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma","volume":"101","author":"Barth","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0185","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/cancers13040682","article-title":"Genomic landscape of Hodgkin Lymphoma","volume":"13","author":"Brune","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101271_bb0190","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.17793","article-title":"9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin study group NIVAHL trial","volume":"196","author":"Gerhard-Hartmann","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101271_bb0195","first-page":"10","article-title":"NFkB pathway and Hodgkin Lymphoma","author":"Jardin","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2025.101271_bb0200","first-page":"2265","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.blre.2025.101271_bb0205","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0210","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2015-02-625293","article-title":"DNA methylation in lymphoma: an opportunity?","volume":"125","author":"Ansell","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0215","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2005-09-3765","article-title":"Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma","volume":"107","author":"Ushmorov","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0220","first-page":"862","article-title":"Unraveling the immune microenvironment in classic Hodgkin Lymphoma: prognostic and therapeutic implications","volume":"12","author":"Georgoulis","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.blre.2025.101271_bb0225","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3390\/cancers13143634","article-title":"Immune microenvironment features and dynamics in Hodgkin Lymphoma","volume":"13","author":"Bertuzzi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101271_bb0230","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/cancers14051360","article-title":"The Hodgkin Lymphoma immune microenvironment: turning bad news into good","volume":"14","author":"Menendez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101271_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1149616","article-title":"An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma","volume":"13","author":"Ferrarini","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101271_bb0240","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic Hodgkin Lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2025.101271_bb0245","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/asheducation-2009.1.491","article-title":"Molecular biology of Hodgkin lymphoma","volume":"2009","author":"Kuppers","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2025.101271_bb0250","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2141.2012.09113.x","article-title":"Genetic lesions of the TRAF 3 and MAP 3K14 genes in classical H odgkin lymphoma","volume":"157","author":"Otto","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101271_bb0255","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.blre.2025.101271_bb0260","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101271_bb0265","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0270","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/gcc.22331","article-title":"Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma","volume":"55","author":"Salipante","year":"2016","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.blre.2025.101271_bb0275","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13353-021-00614-7","article-title":"MicroRNA signature in classical Hodgkin lymphoma","volume":"62","author":"Paczkowska","year":"2021","journal-title":"J Appl Genet"},{"key":"10.1016\/j.blre.2025.101271_bb0280","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3390\/genes13081401","article-title":"The methylation of the p53 targets the genes MIR-203, MIR-129-2, MIR-34A and MIR-34B\/C in the tumor tissue of diffuse large B-cell Lymphoma","volume":"13","author":"Voropaeva","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.blre.2025.101271_bb0285","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1038\/onc.2012.15","article-title":"Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo","volume":"31","author":"Leucci","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2025.101271_bb0290","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3727\/096504016X14685034103473","article-title":"MicroRNA-155 downregulation promotes cell cycle arrest and apoptosis in diffuse large B-cell Lymphoma","volume":"24","author":"Zhu","year":"2016","journal-title":"Oncol Res"},{"key":"10.1016\/j.blre.2025.101271_bb0295","doi-asserted-by":"crossref","first-page":"E1695","DOI":"10.1073\/pnas.1201516109","article-title":"Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma","volume":"109","author":"Babar","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2025.101271_bb0300","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.7150\/thno.53561","article-title":"Targeting miR-21 with NL101 blocks c-Myc\/Mxd1 loop and inhibits the growth of B cell lymphoma","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.blre.2025.101271_bb0305","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1128\/JVI.00570-11","article-title":"Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression","volume":"85","author":"Wang","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2025.101271_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-6917.1000200","article-title":"MicroRNAs as biomarkers of the response to treatment with ABVD scheme in Hodgkin lymphoma","volume":"3","author":"Van Den Berg","year":"2015","journal-title":"J Leuk"},{"key":"10.1016\/j.blre.2025.101271_bb0315","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin Lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2025.101271_bb0320","series-title":"Spatial and Molecular Profiling of the Classic Hodgkin Lymphoma Microenvironment Reveals an Immunosuppressive Mononuclear Phagocyte Network","author":"Stewart","year":"2022"},{"key":"10.1016\/j.blre.2025.101271_bb0325","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105822118","article-title":"Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma","volume":"118","author":"Aoki","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2025.101271_bb0330","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/cells12040606","article-title":"Hodgkin Lymphoma cell lines and tissues express mGluR5: a potential link to Ophelia syndrome and paraneoplastic neurological disease","volume":"12","author":"Schnell","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.blre.2025.101271_bb0335","first-page":"54399","article-title":"Flow-sorting and exome sequencing of the Reed-Sternberg cells of classical Hodgkin Lymphoma","volume":"124","author":"Reichel","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1016\/j.blre.2025.101271_bb0340","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0345","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.blre.2025.101271_bb0350","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0355","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin Lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1171\u201393","key":"10.1016\/j.blre.2025.101271_bb0360","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.blre.2025.101271_bb0365","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0370","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jha2.432","article-title":"Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical Hodgkin lymphoma","volume":"3","author":"Drees","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.blre.2025.101271_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104503","article-title":"Minimal residual disease testing for classical Hodgkin lymphoma: a comprehensive review","volume":"204","author":"Arai","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101271_bb0380","series-title":"Presented at: 63rd American Society of Hematology Annual Meeting & Exposition. AJMC","article-title":"Prognostic value of minimal residual disease (MRD) among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation","author":"Staff A","year":"2021"},{"key":"10.1016\/j.blre.2025.101271_bb0385","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-024-03108-6","article-title":"Hodgkin lymphoma and liquid biopsy: a story to be told","volume":"43","author":"Velasco-Suelto","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.blre.2025.101271_bb0390","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jha2.826","article-title":"Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: correlation with FDG-PET\/CT","volume":"5","author":"Fernandez","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.blre.2025.101271_bb0395","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.seminhematol.2024.05.005","article-title":"Molecular biomarkers in classic Hodgkin lymphoma","volume":"61","author":"Kishida","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2025.101271_bb0400","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101271_bb0405","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed\/refractory Hodgkin Lymphoma","volume":"42","author":"Aoki","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101271_bb0410","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0415","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/cei.12716","article-title":"The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma","volume":"183","author":"Jones","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2025.101271_bb0420","doi-asserted-by":"crossref","first-page":"8147","DOI":"10.53730\/ijhs.v6nS4.11783","article-title":"Epstein barr virus associated Hodgkin and non-Hodgkin lymphoma","volume":"6","author":"Naser","year":"2022","journal-title":"Int J Health Sci"},{"key":"10.1016\/j.blre.2025.101271_bb0425","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/path.2384","article-title":"The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal Centre B cells towards a Hodgkin\u2019s Reed-Sternberg-like phenotype","volume":"216","author":"Vockerodt","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.blre.2025.101271_bb0430","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41598-018-20133-6","article-title":"Frequency of EBV associated classical Hodgkin lymphoma decreases over a 54-year period in a Brazilian population","volume":"8","author":"Campos","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2025.101271_bb0435","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/cas.14833","article-title":"Epstein-Barr virus latent membrane protein-1 upregulates autophagy and promotes viability in Hodgkin lymphoma: implications for targeted therapy","volume":"112","author":"Lin","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.blre.2025.101271_bb0440","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10428190902725813","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly","volume":"50","author":"Wong","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101271_bb0445","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/etm.2023.12294","article-title":"Expression of the immune checkpoint molecules PD-L1 and PD-1 in EBV-associated lymphoproliferative disorders: a meta-analysis","volume":"27","author":"Yu","year":"2024","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.blre.2025.101271_bb0450","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood-2007-05-086934","article-title":"HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma","volume":"110","author":"Niens","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0455","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ng.696","article-title":"A genome-wide association study of Hodgkin\u2019s lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)","volume":"42","author":"Enciso-Mora","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2025.101271_bb0460","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djr516","article-title":"Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups","volume":"104","author":"Urayama","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2025.101271_bb0465","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/ijc.21716","article-title":"Molecular biology of Hodgkin\u2019s and Reed\/Sternberg cells in Hodgkin\u2019s lymphoma","volume":"118","author":"Brauninger","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2025.101271_bb0470","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101271_bb0475","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14737159.7.6.805","article-title":"Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed-Sternberg cell","volume":"7","author":"Roullet","year":"2007","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.blre.2025.101271_bb0480","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jha2.784","article-title":"Current directions in the treatment of classical Hodgkin lymphoma","volume":"4","author":"Keller","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.blre.2025.101271_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397053","article-title":"Immune checkpoint inhibitors in advanced and relapsed\/refractory Hodgkin lymphoma: current applications and future prospects","volume":"14","author":"Milrod","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101271_bb0490","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12185-024-03734-y","article-title":"Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan","volume":"119","author":"Kawasaki","year":"2024","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101271_bb0495","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0500","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/bjh.19534","article-title":"Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma","volume":"205","author":"Brockelmann","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101271_bb0505","series-title":"SWOG S1826, a Randomized Study of Nivolumab (N)-AVD Versus Brentuximab Vedotin (BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL)","author":"Herrera","year":"2023"},{"key":"10.1016\/j.blre.2025.101271_bb0510","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101271_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914780","article-title":"Combined or sequential treatment with immune checkpoint inhibitors and Car-T cell therapies for the Management of Haematological Malignancies: a systematic review","volume":"24","author":"Perez-Moreno","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101271_bb0520","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","author":"Hughes","year":"2024","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.blre.2025.101271_bb0525","doi-asserted-by":"crossref","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.blre.2025.101271_bb0530","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0535","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of Brentuximab Vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin Lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101271_bb0540","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0545","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/biomedicines12050977","article-title":"Beyond chemotherapy: present and future perspectives in the treatment of lymphoproliferative disorders","volume":"12","author":"Massaro","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2025.101271_bb0550","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/17474086.2022.2061947","article-title":"An evaluation of pembrolizumab for classical Hodgkin lymphoma","volume":"15","author":"Manji","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2025.101271_bb0555","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin Lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101271_bb0560","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell Lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm. Phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101271_bb0565","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0570","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/cpf.12868","article-title":"Metabolic tumour volume in Hodgkin lymphoma-a comparison between manual and AI-based analysis","volume":"44","author":"Sadik","year":"2024","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.blre.2025.101271_bb0575","article-title":"Machine learning to predict interim response in pediatric classical Hodgkin Lymphoma using affordable blood tests","volume":"10","author":"Geel","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.blre.2025.101271_bb0580","first-page":"28","article-title":"Lymphoma triage from H&E using AI for improved clinical management","volume":"78","author":"Tsakiroglou","year":"2025","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2025.101271_bb0585","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood-2021-149675","article-title":"Ruxolitinib plus nivolumab in patients with R\/R hodgkin lymphoma after failure of check-point inhibitors: preliminary report on safety and efficacy","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101271_bb0590","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T22:36:18Z","timestamp":1745102178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":118,"alternative-id":["S0268960X25000165"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101271","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101271"}}